12 month, prospective, randomised, open-label comparative study to evaluate the protection of kidney function by basiliximab in a CNI-free regimen in newly kidney transplanted patients (three months post-transplant) who are recipient of one kidney from expanded donor criteria (UNOS criteria)

Trial Profile

12 month, prospective, randomised, open-label comparative study to evaluate the protection of kidney function by basiliximab in a CNI-free regimen in newly kidney transplanted patients (three months post-transplant) who are recipient of one kidney from expanded donor criteria (UNOS criteria)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Basiliximab; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms EXTEND
  • Most Recent Events

    • 25 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top